Gastric Cancer

, Volume 16, Issue 2, pp 183–184

Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

Authors

    • Department of GastroenterologySaitama Cancer Center Hospital
  • Akira Sawaki
    • Department of GastroenterologyAichi Cancer Center Hospital
  • Toshihiko Doi
    • Gastrointestinal Oncology DivisionNational Cancer Center Hospital East
  • Taroh Satoh
    • Department of Medical OncologyKinki University School of Medicine
  • Yasuhide Yamada
    • Department of Gastrointestinal OncologyNational Cancer Center Hospital
  • Yasushi Omuro
    • Department of ChemotherapyTokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
  • Tomohiro Nishina
    • Department of Internal MedicineNational Hospital Organization Shikoku Cancer Center
  • Narikazu Boku
    • Department of GastroenterologyShizuoka Cancer Center
  • Keisho Chin
    • Department of GastroenterologyJFCR Cancer Institute Ariake Hospital
  • Yasuo Hamamoto
    • Department of Medical OncologyTochigi Cancer Center
  • Hiroya Takiuchi
    • Cancer Chemotherapy CenterOsaka Medical College
  • Yoshito Komatsu
    • Third Department of Internal MedicineHokkaido University Hospital
  • Shigehira Saji
    • Department of Medical OncologySaitama Medical University International Medical Center
  • Wasaburo Koizumi
    • Department of GastroenterologyKitasato University East Hospital
  • Yoshinori Miyata
    • Department of GastroenterologySaku Central Hospital
  • Atsushi Sato
    • Department of Internal Medicine, Toyosu HospitalShowa University School of Medicine
  • Eishi Baba
    • Department of Hematology and OncologyKyushu University Hospital
  • Takao Tamura
    • Division of Diabetes, Digestive, and Kidney Diseases, Department of Clinical Molecular MedicineKobe University Graduate School of Medicine
  • Takashi Abe
    • Internal MedicineYamagata Prefectural Central Hospital
  • Atsushi Ohtsu
    • Research Center for Innovative OncologyNational Cancer Center Hospital East
Erratum

DOI: 10.1007/s10120-012-0205-y

Cite this article as:
Yamaguchi, K., Sawaki, A., Doi, T. et al. Gastric Cancer (2013) 16: 183. doi:10.1007/s10120-012-0205-y
  • 589 Views

Erratum to: Gastric Cancer DOI 10.1007/s10120-012-0167-0

In Table 5, the column headings “Grade 3” should be “Grade 3 or 4”.

The corrected table is shown here.
Table 5

Summary of adverse events

 

AVAGASTa (N = 94)

ToGAb (N = 50)

Total (N = 144)

All grades

Grade 3 or 4

All grades

Grade 3 or 4

All grades

Grade 3 or 4

N (%)

N (%)

N (%)

N (%)

N (%)

N (%)

Total

94 (100)

71 (76)

50 (100)

36 (72)

144 (100)

107 (74)

Hematological toxicities

 Neutropenia

63 (67)

45 (48)

34 (68)

20 (40)

97 (67)

65 (45)

 Thrombocytopenia

19 (20)

2 (2)

8 (16)

3 (6)

27 (19)

5 (3)

 Anemia

16 (17)

10 (11)

11 (22)

8 (16)

27 (19)

18 (13)

 Febrile neutropenia

5 (5)

5 (5)

3 (6)

3 (6)

8 (6)

8 (6)

Non-hematological toxicities

 Nausea

84 (89)

18 (19)

44 (88)

7 (14)

128 (89)

25 (17)

 Vomiting

60 (64)

6 (6)

28 (56)

2 (4)

88 (61)

8 (6)

 Diarrhea

51 (54)

4 (4)

24 (48)

2 (4)

75 (52)

6 (4)

 Stomatitis

34 (36)

1 (1)

16 (32)

1 (2)

50 (35)

2 (1)

 Abdominal pain

12 (13)

1 (1)

3 (6)

15 (10)

1 (<1)

 Hand-foot syndrome

54 (57)

2 (2)

23 (46)

1 (2)

77 (53)

3 (2)

 Rash

19 (20)

5 (10)

24 (17)

 Anorexia

83 (88)

27 (29)

46 (92)

10 (20)

129 (90)

37 (26)

 Fatigue

69 (73)

5 (5)

26 (52)

4 (8)

95 (66)

9 (6)

 Peripheral neuropathy

28 (30)

2 (2)

10 (20)

38 (26)

2 (1)

 Renal impairment

17 (18)

3 (3)

27 (54)

44 (31)

3 (2)

 Increased lacrimation

2 (2)

1 (2)

3 (2)

aThe target population of the AVAGAST study was metastatic or inoperable locally advanced adenocarcinoma of the stomach or gastro-esophageal junction

bThe target population of the ToGA study was HER2-positive metastatic or inoperable locally advanced adenocarcinoma of the stomach or gastro-esophageal junction

We sincerely apologize for the errors.

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2012